Muir–Torre syndrome: a variant of the cancer family syndrome

Nigel R Hall, M Angela T Williams, Victoria A Murday, Julia A Newton, D Timothy Bishop

Abstract
Muir–Torre syndrome is characterised by the association of sebaceous tumours of the skin with internal malignancy. In many instances there is a strong family history of cancer and the autosomal dominant mode of inheritance, tumour spectrum, and high incidence of synchronous and metachronous tumours show parallels with the cancer family syndrome or Lynch II syndrome. We report a five generation family with at least two persons displaying the Muir–Torre phenotype, while many other family members have had tumours consistent with classic familial adenomatous polyposis. The majority of tumours are gastrointestinal, urological, and gynaecological, with several persons having multiple primaries. The prognosis appears to be better than would be expected. Sebaceous tumours are a marker for internal malignancy and should prompt a search for occult cancer in the individual person and family members. In documented Muir–Torre families, at risk persons should be entered into screening programmes similar to those used in the Lynch II syndrome.

(J Med Genet 1994;31:627–631)

In 1967 Muir et al. described a subject with multiple sebaceous adenomas and keratoacanthomas of the face who developed squamous cell carcinoma of the larynx, four synchronous colorectal adenocarcinomas, three colorectal polyps, and two duodenal carcinomas over a six year period. The following year Torre independently reported a man with multiple sebaceous tumours in association with ampullary and colonic cancer. Neither of these reports documented family members with the same syndrome. Rulon and Helwig reported two cases where there were relatives with a variety of cancers and others also found affected family members. The significance of this was not fully appreciated until Anderson described a large pedigree; subsequently, Lynch et al. proposed that the Muir–Torre phenotype might be a more florid expression of the Lynch II or cancer family syndrome. Indeed, one of the cases Lynch described was found to be a descendant of Warthin’s family G, which is considered to be the first description of the familial cancer syndrome now termed “Lynch II.”

Following numerous case reports, the Muir–Torre syndrome (McKusick No 158320) has become a well documented cancer associated genodermatosis. The typical skin tumours include sebaceous adenomas, epitheliodomas, and carcinomas; keratoacanthomas and basal cell carcinomas with sebaceous differentiation also occur. The spectrum of internal malignancies is wide, with colorectal carcinomas accounting for about half the cancer diagnoses. Other tumours include transitional cell tumours of the renal tract, carcinomas of the endometrium, ovary, breast, upper gastrointestinal tract (including duodenum), and laryngeal tumours. There is a high incidence of synchronous and metachronous disease, but despite this the tumours may be relatively indolent and the prognosis is often favourable. At least three-quarters of the reported cases of Muir–Torre syndrome also document a family history, though it is of note that the expression of the skin lesions may only be seen in a minority of the family members. We report here a large family from the West Midlands region to characterise further the familial aspects of the syndrome.

Description of the family

PEDIGREE

The proband was referred because he had multiple primary carcinomas and a strong family history of cancer. Twenty one family members were contacted after consent was obtained from their general practitioners and hospital consultants, and a detailed medical history was taken in order to construct the pedigree (figure). All diagnoses were confirmed where possible from hospital notes, pathology records, or death certificates (table 1). We have been able to verify skin lesions typical of the Muir–Torre syndrome in only two persons (IV-12 and IV-14), though other family members have had skin lesions, some of which were excised but not sent for histological analysis.

TUMOUR CHARACTERISTICS

Eleven verified colorectal carcinomas were found in seven family members. On three occasions synchronous carcinomas were present (IV-12, twice in IV-15), and a synchronous adenoma was found in one further person (IV-2). One member (IV-15) had two metachronous lesions, and another (IV-2) developed an anastomotic recurrence nine years after her first primary. The median age of onset for the first colorectal tumour was 47, and six of the seven (86%) were in the right colon. Nine of the tumours had breached the bowel wall and there was lymph node involvement in at least five. Five tumours showed mucinous histology and six were poorly differentiated (table 2).
Pedigree showing skin lesions and cancer diagnosis in family members. Verified cancer diagnoses are shown by full shading and the two subjects with polyps by half shading. Under each symbol is listed the diagnosis (see key for abbreviations) and age at diagnosis. For unaffected members the current age or age at death are shown.

### Table 1  Tumour registry showing details of documented tumours in family members including site and age at diagnosis (method of confirmation)

<table>
<thead>
<tr>
<th>Pedigree ID No</th>
<th>Skin lesions</th>
<th>Neoplasia</th>
<th>Survival after first cancer (y)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>II 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>III 1</td>
<td>Seborrhoeic keratosis, 78 (NH)</td>
<td>Cæcum, 50 (H)</td>
<td>Nasal septum, 65 (H)</td>
<td>15</td>
</tr>
<tr>
<td>III 2</td>
<td>Solar keratoses (NH)</td>
<td>Cæcum with adenoma of ascending colon, 44 (H)</td>
<td>Sarcoma iliac bone, 34 (CR)</td>
<td>0</td>
</tr>
<tr>
<td>III 3</td>
<td>Actinic keratosis, 78 (NH)</td>
<td>Anatomostic recurrence, 53 (H)</td>
<td>Ovary (bilateral), 41 (DC)</td>
<td>40</td>
</tr>
<tr>
<td>IV 1</td>
<td>Solar keratoses (NH)</td>
<td>Cæcum, 50 (H)</td>
<td>Endometrium, 41 (H)</td>
<td>1</td>
</tr>
<tr>
<td>IV 2</td>
<td>Solar keratoses (NH)</td>
<td>Cæcum with adenoma of ascending colon, 44 (H)</td>
<td>Vocal cord polyp, 44 (NH)</td>
<td>22 (alive)</td>
</tr>
<tr>
<td>IV 3</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Endometrium, 46 (H)</td>
<td>8</td>
</tr>
<tr>
<td>IV 4</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Endometrium, 45 (H)</td>
<td>12</td>
</tr>
<tr>
<td>IV 5</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Bladder, 52 (H)</td>
<td>10</td>
</tr>
<tr>
<td>IV 6</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Bladder, muscle invasion, 56 (H)</td>
<td>1</td>
</tr>
<tr>
<td>IV 7</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Ileum, 56 (H)</td>
<td>-</td>
</tr>
<tr>
<td>IV 8</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Brain lesion on CT scan, 56 (NH)</td>
<td>30</td>
</tr>
<tr>
<td>IV 9</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Ureter, 43 (H)</td>
<td>33</td>
</tr>
<tr>
<td>IV 10</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Rectum, 54 (H)</td>
<td>29</td>
</tr>
<tr>
<td>IV 11</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Rectum, 54 (H)</td>
<td>29</td>
</tr>
<tr>
<td>IV 12</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Rectum, 54 (H)</td>
<td>29</td>
</tr>
<tr>
<td>IV 13</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Rectum, 54 (H)</td>
<td>29</td>
</tr>
<tr>
<td>IV 14</td>
<td>Actinic keratosis with CIS, 65 (H)</td>
<td>Transverse colon, 49 (H)</td>
<td>Rectum, 54 (H)</td>
<td>29</td>
</tr>
</tbody>
</table>

**Confirmation:** H = histology, CR = cancer registry, DC = death certificate, NH = no histological confirmation.

**Other abbreviations:** BCC = basal cell carcinoma, CIS = carcinoma in situ, SCC = squamous cell carcinoma, Seb = sebaceous, TCC = transitional cell carcinoma, × 2 = two synchronous tumours.
Four females had endometrial carcinoma, all under the age of 47, and for each this tumour was their first malignancy. Other female genital tract tumours included a bilateral ovarian cancer and a cervical cancer.

PROGNOSIS

Prolonged survival is evident in IV-2 who had endometrial and colorectal primaries and a recurrent colonic carcinoma but remains alive after 22 years, in IV-12 who had five tumours over seven years with liver metastases and subcutaneous lumps for nearly two years, and still maintained a fair standard of health until his death 10 years after his first cancer was diagnosed, in IV-11 who had tumours at three different sites over nine years and survived a further three years, and IV-15 who had two colorectal resections for synchronous cancers and is alive 10 years later. In contrast, a number of family members had a very poor prognosis owing to the inoperability of their tumour or the presence of metastatic disease at presentation.

Discussion

The inheritance of cancer susceptibility in this family is consistent with dominant inheritance but with apparent oversegregation. This may well be because of ascertainment and chance, though it should also be recognised that some cancers may not result from genetic susceptibility. This situation is becoming clearer after our recent demonstration of linkage in this family, and a second Muir–Torre family, to the same locus14 on chromosome 2p that has been reported for the Lynch II syndrome.15 It thus appears that Muir–Torre and Lynch II are allelic, providing support to the findings of other groups16–18 that the Muir–Torre syndrome is often associated with a significant family history and moreover that it represents a phenotypic variant of the cancer family syndrome. Our haplotype analysis of the pedigree shows that the persons with colorectal or endometrial cancer (with or without sebaceous lesions) share the same segment of 2p at this locus, consistent with the view that these two cancer sites are characteristic of the syndrome (manuscript in preparation).

While the majority of other tumours seen in the family have been described in familial syndromes, two tumour sites deserve mention. First, there are two cases of bone sarcomas in this family. Sarcomas have been reported in both Muir–Torre1 and cancer family syndrome,19 but they are very infrequent. Nevertheless, the finding of two bone sarcomas at young ages in relatives in this cancer family is suggestive that they may arise because of a common inherited susceptibility, especially since one sarcoma occurred in an obligate gene carrier (III-1). Preliminary linkage analysis suggests, however, that the mother of the second sarcoma case (IV-7) has not inherited the “disease” haplotype. These discrepant findings do not, therefore, clarify the situation of sarcoma in the Muir–Torre syndrome. Second, IV-8 has a cervical carcinoma, a malignancy which is usually regarded as having a viral rather than inherited aetiology. Lynch et al9 reported three cases of cervical cancer in a Muir–Torre family, yet in none was there any other skin lesion or cancer typical of the syndrome, nor evidence for being a gene carrier, and they questioned the significance of this tumour. As IV-8 does not share the “disease” haplotype, this casts further doubt that cervical cancer is part of the Muir–Torre syndrome. Further molecular genetic investigation of additional families will be required to answer the question of precisely which tumours fall into the syndrome and which arise by chance. Only two affected persons in this family had skin lesions histologically proven to be consistent with those seen in Muir–Torre syndrome, though others may also show the phenotype. This finding is in keeping with other reports of incomplete expression of the skin features in some members.7 18 20 The skin lesions were not as florid as are frequently described and this indicates the importance of careful examination of the skin in those persons who have had cancer at a young age, more than one internal malignancy, or who have a family history of malignancy. Seborrhoeic keratosis and actinic keratosis have been listed in the tumour registry, though they are not recognised as features of the Muir–Torre syndrome: we list them for completeness rather than because we feel they represent the Muir–Torre phenotype. The sebaceous gland tumours seen in the
Muir–Torre syndrome are rare in the general population. Over a 60 year period at the Mayo Clinic, a certain type of sebaceous adenoma, epithelioma, or carcinoma were biopsied. Strikingly, in 25 of these (42%) there was found to be one or more associated internal malignancies, thus fulfilling the criteria for the Muir–Torre syndrome. All but seven of these cases had a family history of malignancy and a family history of cancer was found in four additional patients with skin lesions but no internal malignancy. Thus a sebaceous tumour appears to be a marker for the Muir–Torre syndrome and the finding of a lesion should prompt a thorough search for occult malignancy. The family history of skin lesions with internal malignancy is inconstant, with 28% of lesions appearing before, 12% concurrently with, and 59% after diagnosis of the first malignancy. If a malignancy is not found at presentation of the skin lesion then it would seem prudent to enter the patient into a long term surveillance programme.

The spectrum of remaining tumours in this family, their characteristics, and age of onset are similar to those seen in the Lynch II syndrome. The colorectal cancers occurred at young age and showed a striking right sided predominance. Moreover, the occurrence of a small bowel cancer in IV-11 and a ureteric cancer in IV-12, both very rare in the general population, are characteristic of the Lynch II phenotype.

The most peculiar feature of the Muir–Torre syndrome is the apparently indolent course of the cancers and the resulting relatively good prognosis. While no studies have directly addressed this phenomenon, a retrospective review of 120 persons showing the Muir–Torre phenotype estimated the median survival after first diagnosis of malignancy to be 12 years. Comparing this with a five year survival from colorectal cancer in the general population of only 35% the prolonged survival is notable. Given that collection of pedigree information is facilitated in families where there are more surviving affected members, the apparently improved prognosis may be at least partly explained by an unquantifiable bias in ascertainment. Even harder to explain is the relatively late stage of presentation of the colorectal tumours, with a high proportion of mucinous and poorly differentiated tumours, all of which are generally associated with a poor prognosis.

Mecklin et al noted features of mucinous tumours and poor differentiation in the cancer family syndrome, but the same workers did not find improved survival in their series. Lynch has shown improved survival in his cancer families, but this is not as striking as in Muir–Torre patients.

The high incidence of malignancy in these families makes a very strong case for screening in members likely to be at risk of developing cancer or colorectal polyps. To screen for malignancy in all of the wide spectrum of potential sites, however, would produce a cumbersome and impracticable programme. Screening protocols should be based on those commonly in place for Lynch II families, with concentration on the colorectal, female genital tract, and possibly the renal tract. In some centres, the occurrence of certain sebaceous adenomas or occasionally other tumours would be an indication for additional screening modalities, for example, upper gastrointestinal endoscopy for stomach cancer. Published screening recommendations, however, are scanty and vary considerably between centres. While colorectal screening is well established, the efficacy of pelvic and urological surveillance has yet to be proven. In addition, regular skin examination, advice to bring even minor symptoms to the notice of the family practitioner, and careful genetic counselling should ensure all family members understand the need for screening and are kept under close review.

We are indebted to the many consultants, general practitioners, pathologists, and cancer registrars who have provided the clinical information required to formulate this report, as well as the family members themselves. In particular, our thanks go to Dr A D Cherityawardana (Queen Elizabeth Hospital, Birmingham), Mr K D Fortes Mayer (Manor Hospital, Walsall), and Dr E Conway-Mc Gay (Galway, Eire).

Muir–Torre syndrome: a variant of the cancer family syndrome


631
Muir-Torre syndrome: a variant of the cancer family syndrome.

N R Hall, M A Williams, V A Murday, J A Newton and D T Bishop

*J Med Genet* 1994 31: 627-631
doi: 10.1136/jmg.31.8.627

Updated information and services can be found at:
http://jmg.bmj.com/content/31/8/627

**Email alerting service**

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/